Efraim Shek
Keine laufenden Positionen mehr
Profil
Efraim Shek worked as a Principal at Abbott Laboratories, Cephalon, Inc., and Syntex Corp.
He was also a Senior Vice President-Research & Development at Adamas Pharmaceuticals LLC and a Faculty Member at the University of Florida.
Shek holds a graduate and doctorate degree from the University of Kansas and a graduate degree from The Hebrew University of Jerusalem.
Ehemalige bekannte Positionen von Efraim Shek
| Unternehmen | Position | Ende |
|---|---|---|
| University of Florida | Corporate Officer/Principal | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | - |
| Pharmatec, Inc. | Corporate Officer/Principal | - |
| Syntex Corp. | Corporate Officer/Principal | - |
Ausbildung von Efraim Shek
| University of Kansas | Doctorate Degree |
| The Hebrew University of Jerusalem | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
| Syntex Corp. | Health Technology |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
| Pharmatec, Inc. | Health Technology |
